SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: Biomaven who wrote (7831)2/6/2003 11:28:48 AM
From: tuck  Read Replies (1) | Respond to of 52153
 
Peter,

From Briefing.com:

>>8:55AM Cephalon upped to Overweight from Neutral at JP Morgan (CEPH) 48.11: Firm says news that an ANDA filing for Provigil had been widely anticipated; with this news out of the way, firm concludes that stock has bottomed.

8:54AM Cephalon upgraded at JP Morgan (CEPH) 48.11: JP Morgan upgrades to OVERWEIGHT from Neutral after FDA confirmed acceptence of ANDA filing for Provigil; JP Morgan's Provigil survey results indicate FY04 Provigil sales of $480 mln vs consensus of $330 mln; Morgan Stanley says that it recently met with CEPH management and that meeting was upbeat; reiterates OVERWEIGHT and $63 target.<<

Cheers, Tuck